AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — U.S. net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2019
0
Period ended Dec 31, 2019
Change on a year earlier
–
0 in Q4 2018
History
10 quarters
Since Q3 2017
Sources
5
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 0 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 0 | – | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 0 | -100.0% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 0 | -100.0% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 0 | – | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 0 | – | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 3 | – | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | -3 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 0 | – | Form 10-Q (filed 2018-11-07) ↗ |
Cite this data
StockData. (2026). AbbVie Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — U.S. net revenues ($M) ($M), quarterly Q3 2017–Q4 2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/viekira_us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.